share_log

Acadian Asset Management LLC Invests $1.03 Million in Balchem Co. (NASDAQ:BCPC)

Defense World ·  Sep 8, 2022 05:01

Acadian Asset Management LLC bought a new position in Balchem Co. (NASDAQ:BCPC – Get Rating) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 7,515 shares of the basic materials company's stock, valued at approximately $1,025,000.

Several other institutional investors also recently added to or reduced their stakes in BCPC. American Century Companies Inc. purchased a new position in Balchem in the 4th quarter worth about $671,000. UMB Bank N A MO purchased a new position in Balchem in the 4th quarter worth about $56,000. Lazard Asset Management LLC increased its stake in Balchem by 16.2% in the 4th quarter. Lazard Asset Management LLC now owns 8,458 shares of the basic materials company's stock worth $1,426,000 after buying an additional 1,180 shares during the period. First Horizon Advisors Inc. increased its stake in Balchem by 43.1% in the 4th quarter. First Horizon Advisors Inc. now owns 558 shares of the basic materials company's stock worth $93,000 after buying an additional 168 shares during the period. Finally, Principal Financial Group Inc. increased its stake in Balchem by 8.4% in the 4th quarter. Principal Financial Group Inc. now owns 246,538 shares of the basic materials company's stock worth $41,566,000 after buying an additional 19,098 shares during the period. Hedge funds and other institutional investors own 89.15% of the company's stock.

Get Balchem alerts:

Balchem Trading Up 3.1 %

NASDAQ BCPC opened at $134.35 on Thursday. The company's 50-day simple moving average is $131.75 and its two-hundred day simple moving average is $129.99. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.64 and a current ratio of 2.62. Balchem Co. has a one year low of $110.15 and a one year high of $174.29. The company has a market capitalization of $4.32 billion, a price-to-earnings ratio of 40.22 and a beta of 0.59.

Insider Transactions at Balchem

In other news, VP Gunsteren Job Leonard Van sold 1,000 shares of Balchem stock in a transaction that occurred on Friday, August 12th. The shares were sold at an average price of $131.12, for a total value of $131,120.00. Following the transaction, the vice president now owns 1,430 shares of the company's stock, valued at approximately $187,501.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.60% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. StockNews.com downgraded shares of Balchem from a "buy" rating to a "hold" rating in a research report on Monday, August 1st. HC Wainwright raised their target price on shares of Balchem from $152.00 to $164.00 and gave the company a "buy" rating in a research report on Monday, August 22nd.

About Balchem

(Get Rating)

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.

See Also

  • Get a free copy of the StockNews.com research report on Balchem (BCPC)
  • 3 High Margin Chipmakers Bound to Recover
  • 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
  • REV Group Has A Deep Moat In The World Of EVs
  • Is G-III Apparel Group, Ltd. A Value Trap?
  • Bank Of America Sees Upside In These 2 European Alcohol Stocks

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment